GM-CSF as a therapeutic target in inflammatory diseases

Annemarie van Nieuwenhuijze; Marije Koenders; Debbie Roeleveld; Matthew A Sleeman; Wim van den Berg; Ian P Wicks

doi:10.1016/j.molimm.2013.05.002

GM-CSF as a therapeutic target in inflammatory diseases

Mol Immunol. 2013 Dec;56(4):675-82. doi: 10.1016/j.molimm.2013.05.002. Epub 2013 Aug 8.

Authors

Annemarie van Nieuwenhuijze¹, Marije Koenders, Debbie Roeleveld, Matthew A Sleeman, Wim van den Berg, Ian P Wicks

Affiliation

¹ Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Department of Rheumatology and Advanced Therapeutics, University Medical Centre Nijmegen, Nijmegen, The Netherlands; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.

PMID: 23933508
DOI: 10.1016/j.molimm.2013.05.002

Abstract

GM-CSF is a well-known haemopoietic growth factor that is used in the clinic to correct neutropaenia, usually as a result of chemotherapy. GM-CSF also has many pro-inflammatory functions and recent data implicates GM-CSF as a key factor in Th17 driven autoimmune inflammatory conditions. In this review we summarize the findings that have led to the development of GM-CSF antagonists for the treatment of autoimmune diseases like rheumatoid arthritis (RA) and discuss some results of recent clinical trials of these agents.

Keywords: Autoimmune disease; Autoimmunity; Cytokines; GM-CSF; GM-CSF receptor; Inflammatory disease; Rheumatoid arthritis; T cells; Th17 pathway.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing / immunology
Antibodies, Neutralizing / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / immunology
Clinical Trials as Topic
Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors*
Granulocyte-Macrophage Colony-Stimulating Factor / immunology
Humans
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors*
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
CSF2RA protein, human
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
mavrilimumab
Granulocyte-Macrophage Colony-Stimulating Factor